The Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Data

Basit Öğe Kaydı
dc.authoridDemirturk, Nese/0000-0002-6186-2494
dc.authoridRESAT, MEHMET/0000-0001-8063-4836
dc.authoridGurbuz, Yunus/0000-0002-8772-0769;
dc.contributor.authorGurbuz, Yunus
dc.contributor.authorKocagul-Celikbas, Aysel
dc.contributor.authorOztoprak, Nefise
dc.contributor.authorAygen, Bilgehan
dc.contributor.authorBatirel, Ayse
dc.contributor.authorHabiloglu, Arif Dogan
dc.contributor.authorAktug-Demir, Nazlim
dc.date.accessioned2025-10-11T20:47:41Z
dc.date.available2025-10-11T20:47:41Z
dc.date.issued2024
dc.departmentDüzce Üniversitesien_US
dc.description.abstractObjective: This study aimed to demonstrate the real-life efficacy and safety of glecaprevir / pibrentasvir in the treatment of chronic hepatitis C, as well as to identify the problems caused by the COVID-19 pandemic in the follow-up and treatment of patients. Materials and Methods: The study was conducted retrospectively with the participation of researchers from universities or training and research hospitals. It included patients with chronic hepatitis C who were over 18 years of age, treatment-na & iuml;ve or treatment-experienced, had detectable HCV RNA and were receiving glecaprevir/pibrentasvir treatment Results: Only 188 of the 385 patients who participated in the study came to the follow-up visit 12 weeks after treatment, and all of them had a sustained virological response. It was thought that a significant portion of the 177 patients who did not come to the follow-up visit at 12 weeks after treatment refrained from coming to the hospital due to the COVID-19 pandemic. None of the patients who attended the follow-up visits required treatment discontinuation due to adverse events. Conclusion: Glecaprevir/pibrentasvir is a highly effective and relatively safe drug in the treatment of chronic hepatitis C. The COVID-19 pandemic has negatively affected the follow-up and treatment processes of patients. New measures are needed for the follow-up and treatment of patients with chronic hepatitis C during pandemics.en_US
dc.identifier.doi10.36519/idcm.2024.344
dc.identifier.endpage224en_US
dc.identifier.issn2667-646X
dc.identifier.issue3en_US
dc.identifier.pmid39399749en_US
dc.identifier.scopus2-s2.0-85211167386en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage216en_US
dc.identifier.trdizinid1280203en_US
dc.identifier.urihttps://doi.org/10.36519/idcm.2024.344
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1280203
dc.identifier.urihttps://hdl.handle.net/20.500.12684/21522
dc.identifier.volume6en_US
dc.identifier.wosWOS:001342409100005en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherDoc Design Informatics Co Ltden_US
dc.relation.ispartofInfectious Diseasesand Clinical Microbiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250911
dc.subjectglecapreviren_US
dc.subjectpibrentasviren_US
dc.subjectchronic hepatitis Cen_US
dc.subjectCOVID-19en_US
dc.subjectmulticenter studyen_US
dc.titleThe Efficacy of Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients and the Impact of the COVID-19 Pandemic: Multicenter Real-Life Dataen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu